Deferasirox Novartis.
Novartis is developing a chelating agent, deferasirox, as a once-daily oral therapy for the potential treatment of chronic iron overload in patients needing blood transfusions. By December 2004, data from a phase III trial for iron overload had been released, and filing is expected in the US and EU in the first half of 2005.
Barton
James C
JC
Southern Iron Disorders Center, Birmingham, AL 35209, USA. ironmd@dnamail.com
D000284:Administration, Oral; D000818:Animals; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D003676:Deferoxamine / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015394:Molecular Structure; D013329:Structure-Activity Relationship; D017086:beta-Thalassemia / Q000188:drug therapy
D007502:Iron Chelating Agents; D003676:Deferoxamine